ResearchMoz.us include new market research report"Opportunities in
Human Embryonic Stem Cell (hESC) Products - Trends and Forecasts to 2017
" to its huge collection of research reports.
Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reached four to five days post-fertilization. Human embryonic stem cells are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body.
Full Report With TOC @ http://www.researchmoz.us/opportunities-in-human-embryonic-stem-cell-hesc-products-trends-and-forecasts-to-2017-report.html
Human embryonic stem cells were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts. Federal funds to support hESC research became available on August 9, 2001, when President Bush announced his decision regarding federal funding for hESC research.
Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in wide range of applications, including toxicology testing, tissue engineering, cellular therapies, and basic stem cell biology research. Of particular interest to the medical community is the potential for use of hESCs to heal tissues with naturally limited capacity for renewal, such as the human heart, liver and brain.
However, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin's Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for companies seeking to develop new products.
This market research report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market, from collaborating with WARF to less costly alternatives such as circumventing the claims, conducting research off-shore, and developing embryonic stem cell products for other species.
Key Findings Include:
Trends for hESC Grants, Scientific Publications, and Patents
Market Size Determination for the hESC Product Market
5-Year Market Size Projections (2013-2017)
Embryonic Stem Cell Patent Restrictions and Strategies to Circumvent Claims
Geographical Breakdown (Leading Countries Conducting hESC Research)
Breakdown of Embryonic Stem Cell Research, by Application and Species
Competitive Analysis of hESC Research Supply Vendors
Overview of Specialty Pharma Companies Developing Embryonic Stem Cell Therapies
Overview of Toxicology Testing Legislation (impacting use of hESC in toxicology applications)
Crucial Trends and Unmet Market Needs
And Much More
In summary, this is a must-read industry report for biotech and pharma companies to optimally position themselves to sell hESC products. To profit from this lucrative and rapidly expanding market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the market place, and take advantage crucial hESC trends. Claim this report now to profit from this expanding market or your competition will.
Read All Biotechnology Market Research Reports @ http://www.researchmoz.us/biotechnology-market-reports-30.html
For More Information Kindly Contact:
Email: sales@researchmoz.us
WebSite:http://www.researchmoz.us/
Blog: http://industryresearchnews.blogspot.com
Human embryonic stem cells (hESCs) are stem cells derived from the inner cell mass of a blastocyst, which is a stage reached four to five days post-fertilization. Human embryonic stem cells are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body.
Full Report With TOC @ http://www.researchmoz.us/opportunities-in-human-embryonic-stem-cell-hesc-products-trends-and-forecasts-to-2017-report.html
Human embryonic stem cells were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts. Federal funds to support hESC research became available on August 9, 2001, when President Bush announced his decision regarding federal funding for hESC research.
Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in wide range of applications, including toxicology testing, tissue engineering, cellular therapies, and basic stem cell biology research. Of particular interest to the medical community is the potential for use of hESCs to heal tissues with naturally limited capacity for renewal, such as the human heart, liver and brain.
However, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin's Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for companies seeking to develop new products.
This market research report explores the complex IP landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market, from collaborating with WARF to less costly alternatives such as circumventing the claims, conducting research off-shore, and developing embryonic stem cell products for other species.
Key Findings Include:
Trends for hESC Grants, Scientific Publications, and Patents
Market Size Determination for the hESC Product Market
5-Year Market Size Projections (2013-2017)
Embryonic Stem Cell Patent Restrictions and Strategies to Circumvent Claims
Geographical Breakdown (Leading Countries Conducting hESC Research)
Breakdown of Embryonic Stem Cell Research, by Application and Species
Competitive Analysis of hESC Research Supply Vendors
Overview of Specialty Pharma Companies Developing Embryonic Stem Cell Therapies
Overview of Toxicology Testing Legislation (impacting use of hESC in toxicology applications)
Crucial Trends and Unmet Market Needs
And Much More
In summary, this is a must-read industry report for biotech and pharma companies to optimally position themselves to sell hESC products. To profit from this lucrative and rapidly expanding market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the market place, and take advantage crucial hESC trends. Claim this report now to profit from this expanding market or your competition will.
Read All Biotechnology Market Research Reports @ http://www.researchmoz.us/biotechnology-market-reports-30.html
For More Information Kindly Contact:
Email: sales@researchmoz.us
WebSite:http://www.researchmoz.us/
Blog: http://industryresearchnews.blogspot.com
0 comments:
Post a Comment